Synapse - Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers

Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers Meeting Abstract

Authors:	Fernandez, E. E.; Garralda, E.; Parikh, A.; Italiano, A.; Hollebecque, A.; Marabelle, A.; Friedman, C.; Sullivan, R.; Tschernia, N.; Juarez, M. M. H.; He, K.; Bilusic, M.; Trujillo, M. P.; Su, Z.; Liu, K.; Kopetz, S.; Gulle, J.; Siu, L. L.; Ducreux, M. P.; Tabernero, J.
Abstract Title:	Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
Meeting Title:	Ann. Oncol.
Journal Title:	Annals of Oncology
Volume:	36
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2025-07-01
Language:	English
ACCESSION:	WOS:001545624000131
DOI:	10.1016/j.annonc.2025.05.496
PROVIDER:	wos
Notes:	Meeting Abstract -- 1 -- Source: Wos